Health authorities are endorsing broader use of tirzepatide and semaglutide for type 2 diabetes and obesity, citing their transformative efficacy and strong patient demand. The strategic outlook emphasizes the establishment of standardized protocols to monitor ketone levels and optic function, while ensuring clinicians and patients are aware of potential rare complications. With a moderate overall risk profile, the focus will be on promoting education and supportive frameworks for gradual weight-loss programs.
Title not available for this citation.
“BPC 157 demonstrates well-matched cytoprotective-antiarrhythmic effects, BPC 157 ≈ full cytoprotection/wide-range homeostasis.”
Title not available for this citation.
“DHA induces pigmentation via the Maillard reaction and has demonstrated additional dermatologic applications, including use in vitiligo and erythropoietic protoporphyria and as a potential topical antifungal.”
Title not available for this citation.
“Unregulated melanotan I and II use has caused serious adverse effects, including rhabdomyolysis, renal infarction, and priapism.”
Title not available for this citation.
“While forskolin stimulates melanin production independently of melanocortin receptors and has demonstrated efficacy in animal models, carotenoids, when ingested orally, accumulate in skin and subcutaneous fat, creating a yellow-orange hue.”
Title not available for this citation.
“Diabetes mellitus, including new-onset diabetes after transplant, is a prevalent complication in solid-organ transplant recipients, often necessitating complex glycemic management.”
Title not available for this citation.
“Glucagon-like peptide-1 receptor agonists, including semaglutide and tirzepatide, have shown promising outcomes in the general population, but comparative data in solid-organ transplant recipients are limited.”
Title not available for this citation.
“Tirzepatide may offer advantages in tolerability and rapid glycemic control.”
Title not available for this citation.
“Semaglutide, a GLP-1 receptor agonist, has emerged as a multisystem, disease-modifying agent with benefits that extend well beyond glycemic control.”
Title not available for this citation.
“Across diverse studies, semaglutide consistently produces substantial reductions in body weight and visceral fat.”
Title not available for this citation.
“SELECT demonstrated a significant reduction in major adverse cardiovascular events in adults with overweight or obesity and established atherosclerotic cardiovascular disease (ASCVD), independent of diabetes status.”
Title not available for this citation.
“As international guidelines increasingly position GLP-1 receptor agonists as cardiometabolic therapies, Indian data emphasize the importance of early, phenotype-driven intervention.”
Title not available for this citation.
“Euglycemic ketoacidosis is a rare but increasingly recognized adverse effect related to the use of glucagon-like peptide-1 (GLP-1) receptor agonists.”